Tofacitinib to prevent anti-drug antibody formation against LMB-100 immunotoxin in patients with advanced mesothelin-expressing cancers

• Published in: Frontiers in oncology Vol. 14; p. 1386190
• Main Authors: Skorupan, Nebojsa, Peer, Cody J, Zhang, Xianyu, Choo-Wosoba, Hyoyoung, Ahmad, Mehwish I, Lee, Min-Jung, Rastogi, Shraddha, Sato, Nahoko, Yu, Yunkai, Pegna, Guillaume Joe, Steinberg, Seth M, Kalsi, Shelley S, Cao, Liang, Figg, William D, Trepel, Jane B, Pastan, Ira, FitzGerald, David, Alewine, Christine
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 2024
• Subjects: anti-drug antibodies; immunotoxin; JAK inhibition; mesothelin; pericarditis; immunotoxin; anti-drug antibodies; pericarditis; JAK inhibition; mesothelin
• ISSN: 2234-943X; 2234-943X
• DOI: 10.3389/fonc.2024.1386190

LMB-100 is a mesothelin (MSLN)-targeting recombinant immunotoxin (iTox) carrying a Pseudomonas exotoxin A payload that has shown promise against solid tumors, however, efficacy is limited by the development of neutralizing anti-drug antibodies (ADAs). Tofacitinib is an oral Janus Kinase (JAK) inhibitor that prevented ADA formation against iTox in preclinical studies.
A phase 1 trial testing LMB-100 and tofacitinib in patients with MSLN-expressing cancers (pancreatic adenocarcinoma, n=13; cholangiocarcinoma, n=1; appendiceal carcinoma, n=1; cystadenocarcinoma, n=1) was performed to assess safety and to determine if tofacitinib impacted ADA formation. Participants were treated for up to 3 cycles with LMB-100 as a 30-minute infusion on days 4, 6, and 8 at two dose levels (100 and 140 µg/kg) while oral tofacitinib was administered for the first 10 days of the cycle (10 mg BID). Peripheral blood was collected for analysis of ADA levels, serum cytokines and circulating immune subsets.
The study was closed early due to occurrence of drug-induced pericarditis in 2 patients. Pericarditis with the combination was not reproducible in a transgenic murine model containing human MSLN. Two of 4 patients receiving all 3 cycles of treatment maintained effective LMB-100 levels, an unusual occurrence. Sustained increases in systemic IL-10 and TNF-α were seen, a phenomenon not observed in prior LMB-100 studies. A decrease in activated T cell subsets and an increase in circulating immunosuppressive myeloid populations occurred. No radiologic decreases in tumor volume were observed.
Further testing of tofacitinib to prevent ADA formation is recommended in applicable non-malignant disease settings.
https://www.clinicaltrials.gov/study/NCT04034238.